Diagnostic and Monitoring Strategies for VEXAS Syndrome: Evaluating Sanger Sequencing, NGS, and the SWIM-Score
Journal of Clinical Immunology · 2025-12 · 45 (1)
DOI: 10.1007/s10875-025-01932-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Immunology, online erschienen am 30.09.2025. Verfasst von Lasse von Bornemann Fløe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Ubiquitin-Activating Enzymes, Hereditary Autoinflammatory Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aarhus University Hospital.
Abstract (Originalsprache)
VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic UBA1 variants, but there are no standardized criteria for genetic testing or diagnostics. This study compared Sanger sequencing and next-generation sequencing (NGS) for detecting UBA1 variants in patients with suspected VEXAS, assessed the ability of Sanger sequencing to estimate variant allele fractions (VAFs), and evaluated the Maeda et al. scoring system for selecting patients for genetic testing in a primary cohort and a validation cohort. In the primary cohort of 104 patients, Sanger sequencing identified VEXAS variants in 12%, with no additional cases detected by NGS. Sanger sequencing accurately quantified VAFs ranging from 0.1 to 0.9. In a small longitudinal subset ( n = 3), VAFs in blood correlated with CRP levels, increased over time despite various treatments, but decreased in two patients after initiation of Azacitidine treatment. The novel parameters, VAF in myeloid cells and VEXAS cell concentration, showed promise as exploratory markers for patient monitoring. The Maeda-score, requiring a threshold score of 2 for 100% sensitivity, exhibited low specificity—29% in the primary cohort and 41% in the validation cohort ( n = 62, with 2 carrying VEXAS variants). In contrast, the simplified SWIM-score—based on Skin involvement, Weight loss, Inflammation, and Macrocytic anemia—achieved 100% sensitivity in both cohorts, with higher specificities of 47% and 65%, respectively. In conclusion, Sanger sequencing reliably detected UBA1 variants and quantified VAFs. Monitoring VAF and VEXAS cell concentration may track disease progression, and the SWIM-score demonstrated potential for accurately selecting patients for UBA1 testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Molecular Medicine, Aarhus University Hospital, Brendstrupgaardsvej 21A, 8200 N, Aarhus, Denmark.
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Förderung
- Aarhus University Hospital
Zitieren
APA
von Bornemann Fløe, L., Dyrmose, K. O., Sørensen, C. D., Nørgaard, M., Pedersen, F. K. U., Vad-Nielsen, J., Knudsen, M., Christiansen, M., Bill, M., Rasch, M. N. B., Hauge, E. M., Troldborg, A., Staunstrup, N. H., & Bernth Jensen, J. M. (2025). Diagnostic and Monitoring Strategies for VEXAS Syndrome: Evaluating Sanger Sequencing, NGS, and the SWIM-Score. Journal of Clinical Immunology, 45(1). https://doi.org/10.1007/s10875-025-01932-9
Vancouver
von Bornemann Fløe L, Dyrmose KO, Sørensen CD, Nørgaard M, Pedersen FKU, Vad-Nielsen J, et al. Diagnostic and Monitoring Strategies for VEXAS Syndrome: Evaluating Sanger Sequencing, NGS, and the SWIM-Score. Journal of Clinical Immunology. 2025;45(1). doi:10.1007/s10875-025-01932-9
BibTeX
@article{vonBornemannFle2025,
author = {von Bornemann Fløe, Lasse and Dyrmose, Kirstine Overgaard and Sørensen, Camilla Darum and Nørgaard, Maja and Pedersen, Fie Kirstine Udby and Vad-Nielsen, Johan and Knudsen, Michael and Christiansen, Mette and Bill, Marie and Rasch, Mads Nyhuus Bendix and Hauge, Ellen Margrethe and Troldborg, Anne and Staunstrup, Nicklas Heine and Bernth Jensen, Jens Magnus},
title = {Diagnostic and Monitoring Strategies for VEXAS Syndrome: Evaluating Sanger Sequencing, NGS, and the SWIM-Score},
journal = {Journal of Clinical Immunology},
year = {2025},
volume = {45},
number = {1},
doi = {10.1007/s10875-025-01932-9}
}
EUVIMED